Aminex Therapeutics Obtains $4,000,000 Series A Funding Round

  • Feed Type
  • Date
  • Company Name
    Aminex Therapeutics
  • Mailing Address
    11335 NE 122nd Way Kirkland, WA 98034 USA
  • Company Description
    Aminex Therapeutics, Inc., is a drug development company focused on discovery, development, and commercialization of a new subclass of cancer immunotherapies known as suppressor cell modulators (SCMs).
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The proceeds will be used to finalize Aminex’s preclinical testing and prepare for Phase 1/2A human clinical trials to start midyear 2016. Our patented AMX-513 combination therapy enables the immune system to attack cancer by regulating myeloid-derived suppressor cells.
  • M&A Terms
  • Venture Investor

Trending on Xconomy